bluebird bio, Inc., along with Carlyle and SK Capital Partners, announced that they have obtained all necessary regulatory approvals to finalize the acquisition of bluebird by Carlyle and SK Capital. This follows a previous announcement regarding the merger, which is expected to be completed shortly after the current tender offer concludes. The tender offer is set to expire at midnight on May 12, 2025, unless extended or terminated earlier.
The merger agreement outlines that stockholders will receive $3.00 per share in cash upfront and a contingent value right (CVR) of $6.84 per share upon reaching a sales milestone, totaling a potential value of $9.84 per share. Mark Vachon, chairman of bluebird’s Board of Directors, stated that “the proposed transaction with Carlyle and SK Capital is the only viable solution to generate value for bluebird stockholders.”
Andrew Obenshain, CEO of bluebird bio, remarked on the regulatory approval: “With this update, we have a clear path forward to close the transaction and officially begin the next chapter of bluebird’s journey.”
Stockholders needing assistance can contact Innisfree M&A Incorporated for guidance on tendering their shares.
Founded in 2010, bluebird bio has been a leader in gene therapy with FDA approvals for three therapies within two years. Carlyle is an investment firm managing $441 billion in assets as of December 31, 2024. SK Capital focuses on investments in life sciences and specialty materials sectors.
For further details regarding the tender offer and related documents filed with the SEC, investors are advised to read these carefully before making any decisions.
